Company news

Illumina, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Illumina launches new oncology menu for NovaSeq X Series customers

August 4, 2024

Illumina to Present Upcoming Strategy Update

July 17, 2024

Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

July 10, 2024

Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base

July 8, 2024

Illumina completes the divestiture of GRAIL

June 23, 2024

Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations

June 10, 2024

Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

June 3, 2024

Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares

June 2, 2024

Illumina appoints Everett Cunningham Chief Commercial Officer

June 2, 2024

Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

May 28, 2024

Illumina releases 2023 Corporate Social Responsibility Report

May 27, 2024

Anna Richo joins Illumina's Board of Directors

May 19, 2024

Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL

May 5, 2024

Illumina Reports Financial Results for First Quarter of Fiscal Year 2024

May 1, 2024

Illumina's planned divestment of GRAIL approved by the European Commission

April 11, 2024

Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

April 8, 2024

Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024

April 3, 2024

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023

February 7, 2024

Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world

January 14, 2024

Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023

January 8, 2024

Illumina expands collaboration with Janssen to advance molecular residual disease cancer test

January 4, 2024

The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk

January 3, 2024

Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024

January 3, 2024

Illumina Announces Decision to Divest GRAIL

December 16, 2023

Illumina submits Form 10 to the Securities and Exchange Commission

December 10, 2023

Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries

November 12, 2023

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2023

November 8, 2023

Illumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors

October 31, 2023

Illumina responds to European Commission's divestiture order

October 12, 2023

Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023

October 4, 2023

Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer

September 4, 2023

Illumina expands genomics capabilities in India with opening of Solutions Center

August 16, 2023

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2023

August 8, 2023

Dr. Steven Barnard Appointed Chief Technology Officer

August 8, 2023

Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research

July 31, 2023

Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options

July 24, 2023

Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

July 17, 2023

Illumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery

July 10, 2023

Illumina Ventures to Launch Illumina® Ventures Labs

June 19, 2023

Illumina announces CEO transition plan

June 10, 2023

Illumina releases 2022 Corporate Social Responsibility Report

June 4, 2023

Illumina's Board of Directors elects two experienced Independent Directors to Board

June 1, 2023

Illumina unveils AI software to predict disease-causing genetic mutations in patients

May 31, 2023

Illumina to Host Third Annual Virtual ESG Investor Event on Monday, June 12, 2023

May 30, 2023

Illumina announces preliminary results of annual meeting

May 24, 2023

Illumina Board Chair issues letter to shareholders and urges shareholders to vote the WHITE proxy card FOR all nine of Illumina's nominees

May 17, 2023

Illumina's genomic technologies enable better pathogen preparedness and response

May 15, 2023

Illumina sends letter to shareholders detailing why Illumina's nominees far outmatch Icahn's slate in skills and experience

May 14, 2023

Leading Proxy Advisory Firm ISS Recommends Illumina Shareholders Vote "FOR" Eight of Illumina's Highly Qualified Director Nominees

May 11, 2023

Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's "Plan"

May 7, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 50 decks. Every deck is listed under its year.